Future of HIV: Therapeutics, Vaccines, and Cure

Expert-authored slides reviewing the latest data on investigational antiretroviral agents in later stages of development and on additional investigational approaches to HIV management, including broadly neutralizing antibodies, vaccines, and cure strategies
Babafemi Taiwo, MBBS
Program Director
Daniel R. Kuritzkes, MD
Format: Microsoft PowerPoint (.ppt)
File Size: 477 KB
Released: September 9, 2021

Acknowledgements

Provided by Clinical Care Options, LLC

Contact Clinical Care Options

For customer support please email: customersupport@cealliance.com

Mailing Address
Clinical Care Options, LLC
12001 Sunrise Valley Drive
Suite 300
Reston, VA 20191

Educational grant provided by
Merck Sharp & Dohme Corp.
ViiV Healthcare

Related Content

Dr William Short and Clinical Care Options (CCO): Data fails to support adding agents to intensify ART, switching ART, or adding IL-2 for patients with suboptimal CD4+ cell counts on suppressive ART

William R. Short, MD, MPH, AAHIVS Released: October 15, 2021

Clinical Care Options (CCO) slides from Nicholas Chamberlain, MD, on investigational HIV PrEP strategies in various stages of development

Nicholas Chamberlain, MD Released: October 15, 2021

Results from a study of impact of 13-valent pneumococcal conjugate vaccine on invasive pneumococcal disease in people with HIV at IDWeek 2021 reported by Clinical Care Options (CCO)

Released: October 7, 2021

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.

Continue